Acorda Therapeutics (ACOR) Revenue & Revenue Breakdown

OverviewFinancials Chart Transcripts

Acorda Therapeutics Revenue Highlights

Latest Revenue (Y)

$102.42M

Latest Revenue (Q)

$20.29M

Main Segment (Y)

Product

Acorda Therapeutics Revenue by Period

Acorda Therapeutics Revenue by Year

Date	Revenue	Change
2023-12-31	$102.42M	-13.62%
2022-12-31	$118.57M	-8.14%
2021-12-31	$129.07M	-15.62%
2020-12-31	$152.97M	-20.50%
2019-12-31	$192.41M	-59.19%
2018-12-31	$471.43M	-19.86%
2017-12-31	$588.29M	13.22%
2016-12-31	$519.60M	5.47%
2015-12-31	$492.66M	22.71%
2014-12-31	$401.48M	19.34%
2013-12-31	$336.43M	10.01%
2012-12-31	$305.81M	4.65%
2011-12-31	$292.24M	53.00%
2010-12-30	$191.00M	249.36%
2009-12-31	$54.67M	14.31%
2008-12-31	$47.83M	21.12%
2007-12-31	$39.49M	44.37%
2006-12-31	$27.35M	431.55%
2005-12-31	$5.15M	973.11%
2004-12-31	$479.50K	-43.98%
2003-12-31	$856.00K	-

Acorda Therapeutics generated $102.42M in revenue during NA 2023, up -13.62% compared to the previous quarter, and up 21.73% compared to the same period a year ago.

Acorda Therapeutics Revenue by Quarter

Date	Revenue	Change
2024-03-31	$20.29M	-46.59%
2023-12-31	$37.98M	37.06%
2023-09-30	$27.71M	-6.60%
2023-06-30	$29.68M	33.32%
2023-03-31	$22.26M	-29.28%
2022-12-31	$31.47M	-6.08%
2022-09-30	$33.51M	7.92%
2022-06-30	$31.05M	37.80%
2022-03-31	$22.53M	-39.04%
2021-12-31	$36.97M	17.52%
2021-09-30	$31.46M	-1.04%
2021-06-30	$31.79M	10.13%
2021-03-31	$28.86M	-24.37%
2020-12-31	$38.16M	-28.12%
2020-09-30	$53.09M	57.93%
2020-06-30	$33.62M	19.64%
2020-03-31	$28.10M	-44.35%
2019-12-31	$50.50M	5.81%
2019-09-30	$47.72M	-4.66%
2019-06-30	$50.05M	13.40%
2019-03-31	$44.14M	-36.17%
2018-12-31	$69.15M	-51.58%
2018-09-30	$142.81M	-6.84%
2018-06-30	$153.30M	44.40%
2018-03-31	$106.17M	-43.65%
2017-12-31	$188.40M	33.55%
2017-09-30	$141.06M	1.17%
2017-06-30	$139.44M	16.80%
2017-03-31	$119.39M	-15.10%
2016-12-31	$140.63M	3.70%
2016-09-30	$135.61M	6.40%
2016-06-30	$127.46M	9.97%
2016-03-31	$115.90M	-11.46%
2015-12-31	$130.90M	-11.67%
2015-09-30	$148.20M	30.33%
2015-06-30	$113.71M	13.88%
2015-03-31	$99.85M	-15.29%
2014-12-31	$117.87M	11.24%
2014-09-30	$105.96M	9.09%
2014-06-30	$97.13M	20.63%
2014-03-31	$80.52M	-13.04%
2013-12-31	$92.59M	9.04%
2013-09-30	$84.92M	-2.45%
2013-06-30	$87.05M	21.13%
2013-03-31	$71.86M	-11.79%
2012-12-31	$81.47M	5.21%
2012-09-30	$77.44M	2.35%
2012-06-30	$75.66M	6.19%
2012-03-31	$71.25M	-1.92%
2011-12-31	$72.64M	-21.91%
2011-09-30	$93.03M	42.52%
2011-06-30	$65.28M	6.51%
2011-03-31	$61.29M	-8.25%
2010-12-30	$66.80M	5.00%
2010-09-30	$63.62M	48.53%
2010-06-30	$42.84M	141.36%
2010-03-31	$17.75M	22.90%
2009-12-31	$14.44M	-5.08%
2009-09-30	$15.21M	21.23%
2009-06-30	$12.55M	0.64%
2009-03-31	$12.47M	0.06%
2008-12-31	$12.46M	-0.03%
2008-09-30	$12.47M	9.48%
2008-06-30	$11.39M	-1.11%
2008-03-31	$11.51M	2.66%
2007-12-31	$11.22M	-

Acorda Therapeutics generated $20.29M in revenue during Q1 2024, up -46.59% compared to the previous quarter, and up 64.47% compared to the same period a year ago.

Acorda Therapeutics Revenue Breakdown

Acorda Therapeutics Revenue Breakdown by Product

Annual Revenue by Product

Product/Service	Dec 23	Dec 22	Dec 21	Dec 20	Dec 19
Product	$102.42M	$103.84M	$114.19M	$124.83M	$180.74M
Royalty	$15.11M	$14.88M	$13.14M	$11.67M	-
Ampyra	$63.94M	$84.56M	$98.89M	$163.16M	-
License Revenue	$99.00K	-	-	-	-
License	-	$500.00K	-	-	-
Inbrija	-	-	$29.63M	$24.23M	$15.30M
Milestone Revenue1	-	-	-	$15.00M	-
Other Product	-	-	-	$1.71M	$2.27M

Acorda Therapeutics's latest annual revenue breakdown by segment (product or service), as of Dec 23: Product (56.41%), Ampyra (35.21%), Royalty (8.32%), and License Revenue (0.05%).

Quarterly Revenue by Product

Product/Service	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21	Jun 21	Mar 21	Dec 20	Sep 20	Jun 20	Mar 20	Dec 19	Sep 19	Jun 19
Inbrija	$4.72M	$8.09M	$8.29M	$5.59M	$3.67M	$10.39M	$7.80M	$6.44M	$5.00M	$9.33M	$5.83M	$4.71M	$4.35M	$6.14M	$4.89M	$3.01M	-	-	-	-
Royalty	$2.39M	$5.40M	$2.50M	$3.69M	$3.53M	$3.65M	$3.05M	$3.57M	$3.96M	$4.08M	$3.60M	$3.59M	$3.62M	$3.48M	$3.40M	$2.82M	$3.43M	$3.09M	$2.92M	$2.86M
Product	$17.88M	$32.56M	$25.18M	$25.96M	$18.72M	$27.82M	$29.96M	$27.48M	$18.57M	$32.89M	$27.85M	$28.20M	$25.25M	$34.68M	$34.69M	$30.79M	$24.67M	$47.41M	$44.80M	$47.19M
License Revenue	$23.00K	$31.00K	$34.00K	$23.00K	$11.00K	$500.00K	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Ampyra	$11.50M	$18.70M	$15.72M	$16.91M	$12.61M	$21.11M	$18.18M	$14.90M	$22.52M	$20.03M	$21.76M	$20.25M	$25.34M	$27.34M	$26.08M	$20.12M	$40.78M	$37.65M	$44.18M	-
License	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other Product	-	-	-	-	-	-	-	-	-	-	$21.00K	-	$1.00K	$5.00K	$1.51M	-	$194.00K	$493.00K	$2.26M	-
Milestone	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$15.00M	-	-	-	-	-

Acorda Therapeutics's latest quarterly revenue breakdown by segment (product or service), as of Mar 24: Product (48.98%), Ampyra (31.49%), Inbrija (12.93%), Royalty (6.54%), and License Revenue (0.06%).

Acorda Therapeutics Peer Comparison by Revenue

Ticker	Company	Last Year Revenue	Last Quarter Revenue
PTPI	Petros Pharmaceuticals	$5.82B	$1.42M
PCRX	Pacira BioSciences	$674.98M	$168.57M
LFCR	Lifecore Biomedical	$128.26M	$24.70M
ACOR	Acorda Therapeutics	$102.42M	$20.29M
DERM	Journey Medical	$79.18M	$14.86M
CPIX	Cumberland Pharmaceuticals	$39.55M	$9.09M
BFRI	Biofrontera	$34.01M	$7.83M
UPC	Universe Pharmaceuticals	$32.31M	$13.84M
AGRX	Agile Therapeutics	$19.59M	$5.58M
SNOA	Sonoma Pharmaceuticals	$12.73M	$3.39M
JUPW	Safety Shot	$6.20M	$910.01K
EVOK	Evoke Pharma	$5.18M	$2.65M
AKAN	Akanda	$2.16M	$762.61K
LSDI	Lucy Scientific Discovery	$7.05K	$9.68K
SHPH	Shuttle Pharmaceuticals	-	-
PRFX	PainReform	-	-

ACOR Revenue FAQ

What is Acorda Therapeutics’s yearly revenue?

Acorda Therapeutics's yearly revenue for 2023 was $102.42M, representing a decrease of -13.62% compared to 2022. The company's yearly revenue for 2022 was $118.57M, representing a decrease of -8.14% compared to 2021. ACOR's yearly revenue for 2021 was $129.07M, representing a decrease of -15.62% compared to 2020.

What is Acorda Therapeutics’s quarterly revenue?

Acorda Therapeutics's quarterly revenue for Q1 2024 was $20.29M, a -46.59% decrease from the previous quarter (Q4 2023), and a -8.85% decrease year-over-year (Q1 2023). The company's quarterly revenue for Q4 2023 was $37.98M, a 37.06% increase from the previous quarter (Q3 2023), and a 20.69% increase year-over-year (Q4 2022). ACOR's quarterly revenue for Q3 2023 was $27.72M, a -6.60% decrease from the previous quarter (Q2 2023), and a -17.30% decrease year-over-year (Q3 2022).

What is Acorda Therapeutics’s revenue growth rate?

Acorda Therapeutics's revenue growth rate for the last 3 years (2021-2023) was -20.65%, and for the last 5 years (2019-2023) was -46.77%.

What are Acorda Therapeutics’s revenue streams?

Acorda Therapeutics's revenue streams in c 23 are Product, Royalty, Ampyra, and License Revenue. Product generated $102.42M in revenue, accounting 56.41% of the company's total revenue, down -1.37% year-over-year. Royalty generated $15.11M in revenue, accounting 8.32% of the company's total revenue, up 1.55% year-over-year. Ampyra generated $63.94M in revenue, accounting 35.21% of the company's total revenue, down -24.38% year-over-year. License Revenue generated $99K in revenue, accounting 0.05% of the company's total revenue

What is Acorda Therapeutics’s main source of revenue?

For the fiscal year ending Dec 23, the largest source of revenue of Acorda Therapeutics was Product. This segment made a revenue of $102.42M, representing 56.41% of the company's total revenue.